The main question about Bristol's bid for ImClone: What took so long? More important, what does it mean for biotech?

Seeking to re-establish its cancer credentials, pharmaceuticals maker bids $4.9B for its Erbitux partner.

After mediocre trial results are unveiled, hope fades for a new treatment, and share prices plunge.

At a conference in Chicago, crucial new clues and new debate over how best to treat the disease.